Check for updates

OPEN ACCESS

EDITED BY Esther-Lee Marcus, Herzog Hospital, Israel

REVIEWED BY Tomasz Kostka, Medical University of Lodz, Poland Anna Kęska, Józef Piłsudski University of Physical Education in Warsaw, Poland

*CORRESPONDENCE Chun Li Implication chunilis276@126.com Jianjun Chu Implication chunication chunicatio chunication

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 26 August 2024 ACCEPTED 04 December 2024 PUBLISHED 18 December 2024

CITATION

Li H, Qiu J, Gao Z, Li C and Chu J (2024) Association between waist-to-height ratio and osteoporosis in the National Health and Nutrition Examination Survey: a cross-sectional study. *Front. Med.* 11:1486611. doi: 10.3389/fmed.2024.1486611

COPYRIGHT

© 2024 Li, Qiu, Gao, Li and Chu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Association between waist-to-height ratio and osteoporosis in the National Health and Nutrition Examination Survey: a cross-sectional study

Hailong Li^{1†}, Jianfeng Qiu^{2†}, Zhe Gao³, Chun Li^{4*} and Jianjun Chu⁵*

¹Department of Orthopedics, The Second People's Hospital of Fuyang, Fuyang, Anhui, China, ²School of Artificial Intelligence, Anhui University, Hefei, Anhui, China, ³Huaibei Miner General Hospital, Spinal and Trauma Surgery, Huaibei, Anhui, China, ⁴Department of Orthopedics, The First People's Hospital of Hefei, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China, ⁵Department of Orthopedics, The Second People's Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei, Anhui, China

Background: The link between waist-to-height ratio (WHtR) and osteoporosis (OP) remains a contentious issue in the field of medical research. Currently, the available evidence on this association is deemed insufficient. This topic has garnered significant attention and is a focal point of ongoing investigations.

Methods: A retrospective cross-sectional study was conducted, involving 5,746 participants from the National Health and Nutrition Examination Survey. Data on various demographic and clinical parameters, including age, gender, race, poverty income ratio, educational level, smoking status, drinking status, cardiovascular disease, hypertension, diabetes mellitus, hemoglobin A1c, alanine transaminase, aspartate transaminase, serum total bilirubin, serum creatinine, uric acid, blood urea nitrogen, serum sodium, serum phosphorus, total calcium, serum potassium, and serum iron, were collected from all participants. The main analytical methods utilized in this study were multivariable logistic regression, restricted cubic splines, and threshold effect analysis to investigate the association between WHtR and OP.

Results: A total of 5,746 elderly participants were enrolled, with a median age of 69.3 years. Compared with individuals with lower WHtR Q1 (≤ 0.36 to ≤ 0.56), the adjusted OR values for WHtR and OP in Q2 (<0.56 to ≤ 0.61), Q3 (<0.61 to ≤ 0.66), and Q4 (<0.66 to ≤ 0.94) were 0.63 (95% CI: 0.47–0.85, p = 0.003), 0.53 (95% CI: 0.37–0.76, p < 0.001), and 0.49 (95% CI: 0.35–0.68, p < 0.001), respectively. The association between WHtR and OP exhibited an L-shaped curve (nonlinear, p = 0.008) with an inflection point of roughly 0.57. The OR for the presence of OP was 0.50 (95% CI: 0.31–0.82, p = 0.007) in participants with WHtR <0.57. There was no association between WHtR and OP in participants with WHtR ≥ 0.57 .

Conclusion: The association between WHtR and OP showed an L-shaped curve, with an inflection point at around 0.57.

KEYWORDS

waist-to-height ratio, osteoporosis, elderly people, NHANES, cross-sectional study

1 Introduction

Osteoporosis (OP) is a disease defined by a decrease in bone mass and density, resulting in diminished bone strength and an increased risk of fractures, particularly in the hip and spine. The incidence of OP in the United States is approximately 12.6% among persons aged 50 years and older (1). Currently, due to the continuous advancement of the worldwide population aging, the annual number of patients suffering from fractures caused by OP is as high as 8.9 million (2), indicating that there is one individual with OP who experiences fractures every 3 s (3). The significant medical and societal impact of this issue has generated widespread public attention, highlighting the crucial need to investigate the factors associate with OP in order to prevent its occurrence.

Numerous osteoporosis risk factors have been proposed in previous studies, such as age, gender, obesity, smoking, alcohol consumption, calcium intake, physical activity, and others. Among these, obesity is particularly significant due to its complex interactions with bone metabolism (4). Assessment of obesity, particularly central obesity, is crucial in understanding its relationship with OP. Common indicators include body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR). While BMI provides a general measure of obesity, WC, WHR, and WHtR offer insights into the distribution of fat, with abdominal fat being more closely related to metabolic complications and bone health (5). Central obesity is characterized by excessive fat accumulation around the abdomen and can have an impact on bone health through chronic inflammation, hormonal changes, and increased mechanical loading (6). In addition, when evaluating central obesity, WC and WHR may be influenced by factors such as gender or ethnicity, whereas the WHtR is comparatively less impacted (7). Therefore, the WHtR is the most pragmatic approach for evaluating abdominal obesity (8). However, the relationship between WHtR and OP remains ambiguous (4, 5, 9). Thus, it is highly meaningful to investigate the association between WHtR and OP across different demographic groups in order to assess if the WHtR and the OP were correlated. The study aims to explore the association between WHtR and OP.

To achieve these objectives, a cross-sectional research was conducted which involved elderly people from the National Health and Nutrition Examination Survey (NHANES). This research design enables the investigation of the relationships between WHtR and OP within a substantial and varied sample group.

2 Method

2.1 Data source

This cross-sectional study employed NHANES data from 2005 to 2010, 2013 to 2014, and 2017 to 2018, which was conducted by the Centers for Disease Control and Prevention (10). The objective of the NHANES project was to evaluate the health and nutritional status of non-institutionalized Americans using a stratified multistage probability survey (11). The NHANES collects demographic and in-depth health information via home visits, screening, and laboratory testing conducted by a mobile examination center (MEC). The NHANES was authorized by the National Center for Health Statistics (NCHS) Ethics Review Committee, and all participants completed

written informed consent forms before participation. The secondary analysis did not require additional Institutional Review Board approval (12). The NHANES data are accessible via the NHANES website.¹ The study population consisted of individuals aged 60 years and older who had completed an interview. Individuals with incomplete data on variables such as stand height, waist circumference, bone density assessment, or covariates were excluded from the analysis.

2.2 Determination of BMD and the diagnosis of OP

The bone mineral density (BMD) levels were measured in several areas (total femur, femur neck, and lumbar spine) in the NHANES study using dual-energy X-ray absorptiometry (DXA) with Hologic QDR-4500A fan-beam densitometers (Hologic, Inc., Bedford, Massachusetts). The left hip was typically examined, while the right hip was only imaged in cases where the patient reported a fracture, pin, or replacement in the left hip. The BMD of the lumbar spine was determined by averaging the BMD measurements obtained from the first to fourth vertebrae in the lumbar region. Pregnant patients, individuals with a history of radiographic contrast material, those with bilateral hip fractures, replacements, or pins, and those exceeding 450 lbs. in weight were excluded from the DXA examination. In this study, the diagnosis of OP was established by referencing relevant literature (13, 14) and employing established methods to convert the BMD levels of the femoral neck and lumbar spine into T-scores. Individuals were classified as suffering from OP, osteopenia, or having normal bone density according to the *T*-score: $\leq -2.5, -2.5 < T$ -score $\leq -1,$ and *T*-score > -1, respectively. Patients with osteopenia and those with normal bone density were classified as non-OP.

2.3 Waist-to-height ratio (WHtR)

The WHtR was determined by dividing the waist circumference by the standing height of the participant.

2.4 Covariate assessment

Drawing from existing research and clinical insights, the selection of covariates in this study primarily encompasses demographic variables, metabolic and chronic disease states, along with biochemical parameters.

The modified model includes demographic characteristics. Gretl Hendrickx et al. have asserted that age and gender correlate with osteoporosis (15). Relevant investigations have also substantiated the connection between ethnicity, poverty-income ratio (PIR), and educational attainment with bone mineral density (16–18). Lifestyle variables such as smoking and alcohol intake affect the incidence of osteoporosis (15). A literature study by Mahmood Safaei et al. demonstrates that age, gender, ethnicity, PIR, educational attainment,

¹ http://www.cdc.gov/nchs/nhanes.htm, last accessed on May 1, 2024

smoking, and alcohol intake are factors of obesity (19). Consequently, these demographic determinants have a dual function in the etiology of osteoporosis and obesity, highlighting their importance in the updated model.

Previous research has demonstrated a correlation between obesity and osteoporosis in individuals with metabolic and chronic illnesses. A study by Bo Wu et al. showed that diabetes mellitus (DM) may result in secondary osteoporosis (20). A review of the literature by Michel et al. also found that people who have had osteoporotic fractures or low bone mineral density are more likely to have coronary artery disease and stroke than people who do not have osteoporosis. In contrast, those with cardiovascular disorders have a heightened risk of bone loss and osteoporotic fractures (21). Cappuccio FP et al. indicated that raised blood pressure in older white women is associated with greater femoral neck bone loss, suggesting a linkage between osteoporosis and hypertension (22). Research indicates that obesity correlates with a heightened risk of several chronic and metabolic disorders, such as asthma, diabetes, hypertension, and cardiovascular diseases (CVD) (19).

Adjustments were made to certain biochemical markers in the model for the following reasons: HoJeongDo et al. indicated that liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), have a negative correlation with bone mineral density (BMD) (23). Liu Chenbin et al. elucidated the relationship between obesity and liver enzymes (AST, ALT) (24). Researchers have recorded a correlation between total bilirubin and BMD (25). Zara Jenko-Plaznikar et al. found a decrease in blood bilirubin concentrations in overweight healthy individuals and a negative correlation with abdominal obesity (26). Additionally, studies employing Mendelian randomization revealed a robust correlation between glycated hemoglobin and estimated bone mineral density (eBMD), potentially facilitated by non-glycemic pathways such as red blood cell indices (27). A research study found that lifestyle weight reduction programs effectively improve glycated hemoglobin levels in individuals with type 2 diabetes mellitus (T2DM) across various ethnic groups (28). In addition, UgurA et al.'s study on biochemical markers related to renal function found that high blood urea nitrogen levels are a sign of lower bone mineral density in the femoral neck (29). Previous investigations have also revealed a correlation between obesity and urea nitrogen (30). Guan Yu et al. identified a favorable connection between serum creatinine and BMD in elderly Chinese individuals with normal renal function (31). Mehl Rubin et al.'s research reveals that obese women have elevated average serum creatinine and creatinine clearance rates compared to healthy normalweight women (32). The investigation by Yan Dandan et al. showed that uric acid has a protective influence on bone metabolism in Chinese postmenopausal women (33). A research study indicated that elevated blood uric acid (SUA) levels correlate with a heightened risk of obesity (34). Moreover, prior research has shown correlations between obesity and osteoporosis with blood electrolytes, including sodium, potassium, iron, phosphorus, and total calcium (35-42). Wang et al. further showed that sufficient vitamin D consumption decreases the incidence of osteoporosis in postmenopausal women in the United States, particularly in those aged 65 and above (43). Hajhashmi et al. conducted a meta-analysis that revealed a negative correlation between blood vitamin D levels and the incidence of abdominal obesity in adults (44).

NHANES researchers developed standardized questionnaires to gather demographic data, such as gender (male or female), age, PIR, race (non-Hispanic White, non-Hispanic Black, Mexican American, other Hispanic, or other race, including multi-racial), and education level (less than high school: less than 9th grade and 9-11th grade (including 12th grade with no diploma); high school or equivalent: high school graduate/GED or equivalent; above high school: some college or AA degree and college graduate or above). You can classify smoking status into three categories: never (less than 100 cigarettes), former (more than 100 cigarettes but stopped), and current (more than 100 cigarettes and still smoke). Drinking status (never: drank less than 12 drinks in a lifetime; former: drank more than 12 drinks in 1 year but abstained from alcohol the previous year, or more than 12 drinks overall) Currently, heavy alcohol consumption is defined as having three or more drinks per day for women, four drinks per day for men, or binge drinking on five or more days per month (four drinks on the same occasion for women, five drinks on the same occasion for men). Presently, moderate alcohol consumption is defined as two or more drinks for women, three for men, or binge drinking for more than 2 days per month. Currently, mild alcohol consumption is defined as ≤ 1 drink for women and ≤ 2 drinks for men per day. The self-reported CVD history included previous diagnoses of heart failure, coronary heart disease, angina, heart attack, or stroke. In order to calculate the mean blood pressure, disregard diastolic measurements of zero unless all diastolic measurements are zero. We considered a single reading as the mean value. To calculate several readings, do not include the first reading in the computation. The diagnosis of hypertension occurred when the systolic blood pressure reached or exceeded 140 mmHg or when the diastolic blood pressure reached or exceeded 90 mmHg. A doctor's diagnosis, glycohemoglobin (HbA1c) values >6.5%, fasting glucose levels \geq 7.0 mmol/L, blood glucose levels \geq 11.1 mmol/L from a random 2-h oral glucose tolerance test, or the use of diabetes medicine or insulin are the diagnostic criteria for DM. We followed standardized protocols to measure the following: hemoglobin A1c (HbA1c), ALT, AST, serum total bilirubin, serum creatinine, uric acid, blood urea nitrogen (BUN), serum sodium, serum phosphorus, total calcium, serum potassium, and serum iron. The NHANES website provides further information.

2.5 Statistical analysis

In accordance with the NHANES analytic criteria, the current study accounted for intricate sample designs and sampling weights (45). A weighted analysis using Wtmec2 year weights was conducted. We included data from NHANES for the years 2005–2010, 2013–2014, and 2017–2018. In this research, the sample weights for data analysis were computed in the following manner: The sampling weight was calculated as $1/5 \times$ wtmec2yr.

Categorical variables are shown as unweighted counts (weighted percentages), whereas continuous variables are expressed using the mean (standard deviation, SD) or median (interquartile range, IQR), as applicable. One-way analyses of variance were used for data with a normal distribution, Kruskal-Wallis tests were used for data with a skewed distribution, and chi-square tests were used for categorical variables to look at the differences between the groups. Logistic regression models were used to ascertain the odds

ratios (OR) and 95 percent confidence intervals (95% CIs) for the association between WHtR and OP. Our model adjustment was based on the following principles: Model 1 included variables, such as sex and uric acid, whose effect values changed by more than 10%. Model 2 was adjusted for adding variables with *p*-values below 0.05 in the univariate analysis based on model 1, thus further including age, race, PIR, educational level, smoking status, drinking status, DM, HbA1c, ALT, and serum total bilirubin and serum phosphorus. Model 3 was the fully adjusted model, which also included adjustments for CVD, hypertension, AST, serum creatinine, BUN, serum sodium, total calcium, serum potassium, and serum iron, all based on Model 2. Furthermore, a restricted cubic spline (RCS) regression analysis was conducted using 3 knots as recommended by Harrell (46). This analysis aimed to evaluate the linearity and investigate the dose-response relationship between WHtR and OP while controlling for other factors in Model 3. To identify the threshold effect, we have enhanced a two-piecewise linear regression model based on the smoothing curve. This model also takes into account possible confounders in Model 3.

Interactions and stratified analyses were performed based on gender (male vs. female), race (Hispanic vs. non-Hispanic), education level ($\leq 12y$ vs. >12y), smoking status (never vs. former or current), drinking status (never vs. former or current), and diabetes mellitus (DM) (yes vs. no). The study used logistic regression models to measure heterogeneity among the subgroups as well as likelihood ratio testing to examine their interactions. In order to assess the strength and reliability of our findings, we further included patients who had data on blood total 25-hydroxyvitamin D for sensitivity analyses.

All of these models' computed effect sizes and p values were presented and contrasted. R Statistical Software (Version 4.2.2, The R Foundation)² and the Free Statistics analytic platform (Version 1.9, Beijing, China)³ (47) were used for all analyses. FreeStatistics is a software suite that offers user-friendly interfaces for doing common analyses and visualizing data. R serves as the statistical engine, and Python implements the graphical user interface (GUI). It was specifically created for doing analysis that can be replicated and for engaging in computing that allows for interaction. A two-sided p value less than 0.05 was deemed to be statistically significant.

3 Results

3.1 Study population

Of the 19,087 participants of the NHANES 2005–2018 aged \geq 60y, 13341were excluded for the following reasons:

- Missing data on body measures (n = 2,907).
- Missing data on OP detection (n = 8,781).
- Missing data on covariates (*n* = 1,653).

Thus, 5,746 participants were included in the analysis (Figure 1).

3.2 Baseline characteristics

Table 1 displays the fundamental characteristics of the 5,746 individuals included in the research, categorized based on their WHtR quartiles. A total of 651 people, or 11% of the population, had OP. The mean age of the research participants was 69.32 (6.80) years, and 2,742 (53.29%) people were female. Compared to those with lower WHtR, those with higher WHtR were more likely to be non-Hispanic White, have lower family income, and be more likely to be female. They also had lower current smoking and drinking rates, as well as a higher prevalence of hypertension, diabetes, and CVD; had lower levels of serum iron; and had higher levels of HbA1c, uric acid, ALT, AST, and BUN.

3.3 Relationship between WHtR and osteoporosis

The univariate analysis revealed that age, gender, race, education level, smoke status, drink status, DM, HbA1c, Alt, total bilirubin, uric acid, and serum phosphorus were all shown to be associated with OP, as indicated by Table 2.

When the WHtR was examined using quartiles, a significant negative correlation was seen between WHtR and OP after accounting for any confounding factors. When comparing individuals with a lower WHtR in the range of Q1 (≤ 0.36 to \leq 0.56), the adjusted odds ratio (OR) values for WHtR and OP in the Q2 range (<0.56 to \leq 0.61), Q3 range (<0.61 to \leq 0.66), and Q4 range (<0.66 to ≤ 0.94) were 0.63 (95% CI: 0.47–0.85, p = 0.003), 0.53 (95% CI: 0.37–0.76, *p* < 0.001), and 0.49 (95% CI: 0.35–0.68, p < 0.001), respectively, as shown in Table 3. The relationship between WHtR and OP showed an L-shaped curve, indicating a nonlinear correlation (p < 0.001) in restricted cubic splines (RCS) analysis (Figure 2). In the threshold analysis, the odds ratio (OR) for developing OP was 0.50 (95% confidence interval [CI]: 0.31-0.82, p = 0.007) among patients with WHtR less than 0.57 (Table 4). With each 0.1 rise in WHtR, the chance of OP is lowered by 50%.

3.4 Subgroup analyses


A stratified analysis was conducted in many subgroups to evaluate possible impact alterations on the association between WHtR and OP. There were no notable interactions seen in any subgroups when analyzing the data based on gender, race, education level, smoking status, drinking status, and DM (Figure 3).

3.5 Sensitivity analysis

The link between WHtR and OP remained consistent after adjusting for the covariate of vitamin D. A lower WHtR in Q1 (\leq 0.36 to \leq 0.56) was linked to a higher risk of OP. The adjusted odds ratio (OR) for WHtR and OP was 0.47 (95% CI: 0.32–0.70, *p* < 0.001) in Q3

² http://www.R-project.org

³ http://www.clinicalscientists.cn/freestatistics



 $(<0.61 \text{ to } \le 0.66) \text{ and } 0.52 (95\% \text{ CI: } 0.36-0.76, p = 0.001) \text{ in } Q4 (<0.66 \text{ to } \le 0.94) (Table 5).$

4 Discussion

This cross-sectional study employed data from 5 cycles of NHANES to analyze the relationship between OP and WHtR in the U.S. elderly population. The findings, after controlling for potential confounding variables, established a negative correlation between WHtR and the occurrence of OP. Notably, restricted cubic spline (RCS) analysis showed that WHtR and OP prevalence had a nonlinear inverse relationship. A threshold was found at WHtR = 0.57 using threshold effect analysis. An increase in WHtR within a certain range was associated with a reduced risk of OP. Subgroup analyses further confirmed the stability of this inverse correlation across different populations. Ultimately, sensitivity analysis reinforced the robustness and consistency of the research outcomes.

Prior research has assessed the correlation between obesity and OP, or bone density, using several anthropometric measures. The BMI is a commonly used metric to assess obesity. However, as research has progressed, the obesity paradox has emerged, raising questions about the accuracy of BMI as a measure of obesity among researchers (48, 49). The reason is likely that BMI only assesses general obesity and disregards body fat distribution (50). Nevertheless, several investigations have shown a strong correlation between the allocation of fat and bone metabolism, particularly in the case of abdominal obesity (51, 52). WC, WHR, and WHtR are measurements used to evaluate the distribution of abdominal fat. These measurements have been used in several studies to examine the relationship between central obesity and bone health (4, 5). Prior research has examined the connections between WC or the WHR and BMD or OP. However, the results have been inconclusive, mostly due to the significant effects of gender, age, and race (8). The WHtR has some benefits when compared to other measures of central obesity, such as WC or

TABLE 1 Population characteristics by categories of WHtR.

Characteristic	Waist-to-height ratio									
	Total	Q1 [0.36, 0.56]	Q2 [0.56, 0.61]	Q3 [0.61, 0.66]	Q4 [0.66, 0.94]	<i>p</i> -value				
NO.	5,746	1,437	1,436	1,436	1,437					
Age (year), Mean (SD)	69.32 (6.80)	69.42 (7.03)	69.47 (6.86)	69.53 (6.78)	68.86 (6.52)	0.147				
Gender, <i>n</i> (%)										
Male	3,004 (46.71)	767 (41.83)	817 (51.91)	795 (52.23)	625 (41.15)	< 0.001				
Female	2,742 (53.29)	670 (58.17)	619 (48.09)	641 (47.77)	812 (58.85)					
Race, n (%)										
Non-Hispanic White	3,157 (81.13)	795 (80.20)	783 (80.80)	785 (81.22)	794 (82.33)	< 0.001				
Non-Hispanic Black	1,074 (7.56)	322 (8.32)	254 (7.25)	242 (7.01)	256 (7.62)					
Mexican American	729 (3.97)	106 (2.23)	178 (3.97)	221 (4.90)	224 (4.83)					
Other Hispanic	441 (2.99)	71 (2.04)	114 (3.31)	127 (3.35)	129 (3.31)					
Other Race*	345 (4.35)	143 (7.21)	107 (4.67)	61 (3.52)	34 (1.90)					
PIR, Mean (SD)	3.13 (1.54)	3.27 (1.56)	3.18 (1.55)	3.1 0 (1.54)	2.96 (1.50)	0.002				
Education level, n (%)										
Less than high school	1,656 (18.39)	359 (15.66)	415 (18.93)	420 (18.80)	462 (20.24)	0.003				
High school or equivalent	1,417 (26.11)	325 (22.29)	348 (26.97)	383 (27.98)	361 (27.32)					
Above high school	2,673 (55.50)	753 (62.05)	673 (54.10)	633 (53.22)	614 (52.44)					
Smoking status, n (%)					I					
Never	2,706 (48.18)	679 (51.06)	695 (50.27)	664 (45.0 9)	668 (46.16)	< 0.001				
Former	2,309 (40.89)	498 (35.23)	558 (37.75)	630 (45.43)	623 (45.35)					
Now	731 (10.94)	260 (13.71)	183 (11.98)	142 (9.48)	146 (8.49)					
Drinking status, <i>n</i> (%)										
Never	930 (13.81)	220 (13.10)	232 (14.35)	236 (13.73)	242 (14.08)	0.019				
Former	1,382 (19.86)	314 (17.11)	330 (18.62)	359 (22.61)	379 (21.20)					
Mild	2,377 (46.80)	659 (51.87)	600 (48.19)	574 (42.96)	544 (44.00)					
Moderate	620 (12.49)	155 (12.37)	152 (11.97)	154 (11.57)	159 (14.01)					
Heavy	437 (7.05)	89 (5.55)	122 (6.88)	113 (9.12)	113 (6.72)					
CVD, n (%)				1						
No	4,443 (78.35)	1,162 (83.00)	1,146 (80.91)	1,077 (75.96)	1,058 (73.39)	< 0.001				
Yes	1,303 (21.65)	275 (17.00)	290 (19.09)	359 (24.04)	379 (26.61)					
Hypertension, <i>n</i> (%)			1	1	<u> </u>					
No	1767 (33.50)	597 (45.78)	467 (36.38)	409 (30.59)	294 (20.94)	< 0.001				
Yes	3,979 (66.50)	840 (54.22)	969 (63.62)	1,027 (69.41)	1,143 (79.06)					
DM, n (%)										
No	3,991 (74.04)	1,205 (88.65)	1,057 (79.05)	933 (69.78)	796 (58.30)	< 0.001				
Yes	1755 (25.96)	232 (11.35)	379 (20.95)	503 (30.22)	641 (41.70)					
HbA1c(%), Mean (SD)	5.89 (0.90)	5.63 (0.68)	5.81 (0.82)	5.97 (0.94)	6.16 (1.05)	< 0.001				
Uric acid (mg/dl), Mean (SD)	5.64 (1.41)	5.10 (1.35)	5.55 (1.33)	5.84 (1.35)	6.07 (1.41)	< 0.001				
Serum sodium (mmol/L), Mean (SD)	139.71 (2.58)	139.72 (2.57)	139.61 (2.55)	139.87 (2.56)	139.65 (2.64)	0.385				
Serum phosphorus (mg/dl) Mean (SD)	3.75 (0.55)	3.81 (0.57)	3.75 (0.53)	3.71 (0.54)	3.71 (0.55)	< 0.001				
Total calcium (mg/dl), Mean (SD)	9.45 (0.37)	9.46 (0.36)	9.47 (0.37)	9.44 (0.37)	9.44 (0.39)	0.258				
Serum potassium (mmol/L), Mean (SD)	4.09 (0.38)	4.07 (0.38)	4.08 (0.36)	4.09 (0.39)	4.10 (0.40)	0.617				
Serum iron (ug/dl), Mean (SD)	86.55 (31.39)	90.14 (32.94)	87.60 (31.52)	87.95 (31.26)	80.49 (28.87)	<0.001				

(Continued)

Characteristic	Waist-to-height ratio								
	Total	Q1 [0.36, 0.56]	Q2 [0.56, 0.61]	Q3 [0.61, 0.66]	Q4 [0.66, 0.94]	<i>p</i> -value			
ALT (u/L), Median [IQR]	20.00 [16.00, 25.39]	19.00 [16.00,24.00]	20.00 [16.00,25.00]	20.00 [16.00,26.00]	21.00 [17.00,27.00]	0.001			
AST (u/L), Mean (SD)	24.92 (11.07)	25.35 (8.28)	25.35 (8.28) 24.66 (8.23)		25.48 (16.72)	0.007			
Serum total bilirubin(mg/dl), Mean (SD)	0.70 (0.30)	0.73 (0.30)	0.71 (0.28)	0.70 (0.29)	0.66 (0.32)	0.002			
Serum creatinine (mg/dl), Mean (SD)	0.98 (0.41)	0.96 (0.46)	0.98 (0.33)	1.01 (0.46)	0.99 (0.38)	0.004			
BUN (mg/dl), Mean (SD)	16.42 (6.41)	15.96 (6.01)	16.04 (5.59)	16.78 (6.32)	16.91 (7.51)	0.001			
Osteoporosis, n (%)									
No	5,095 (87.93)	1,180 (81.34)	1,282 (88.72)	1,311 (90.48)	1,322 (91.40)	< 0.001			
Yes	651 (12.07)	257 (18.66)	154 (11.28)	125 (9.52)	115 (8.60)				

TABLE 1 (Continued)

WHtR, waist to height ratio; Q, quartiles; * Other not defined by the NHANES but it does include multi-racial and non-Hispanic Asian; PIR, poverty-to-income ratio; CVD, Cardiovascular Disease; DM, diabetes mellitus, HbA1c, hemoglobin A1c; ALT, alanine transaminase; AST, alanine transaminase; BUN, blood urea nitrogen.

WHR. WHtR is less impacted by factors such as sex or ethnicity (7). Moreover, our investigation reveals substantial variations in biochemical markers across different WHtR groups, indicating the effectiveness of WHtR as an indicator of central obesity and its significance for hepatic and renal metabolic profiles. This aligns with the findings of Huang et al., who found that WHtR serves as an independent and superior predictor of hyperuricemia (53). Chen et al.'s study also supports our findings, identifying WHtR as the most effective anthropometric measure for assessing adult ALT levels (54). These converging findings highlight the significance of WHtR in assessing the risk of obesity-related metabolic diseases. In addition, the most current United Kingdom obesity recommendations (55) have advised using WHtR as a marker of obesity. Therefore, the WHtR is a reliable metric used to evaluate the correlation between obesity and OP or BMD.

Tian et al. conducted a study in 8457 people using quantitative heel ultrasonography (QUS) to quantify BMD. They then examined the relationship between WHtR, BMD, and OP. The researchers determined that an increase in WHtR was strongly linked to greater estimated bone mineral density BMD and a reduced risk of OP. Furthermore, they noted that the older participants appeared to be more inclined to experience the fat-protect-bone effects (4). Nevertheless, several studies have shown a detrimental correlation between WHtR and BMD (5, 56). Jongseok Lee et al. examined the relationship between WHtR and BMD using data from 2060 Korean adolescents aged 10-19 years. The data was obtained from the Korea National Health and Nutrition Examination Survey (KNHANES), performed between 2008 and 2011. Their findings indicate a nonlinear "inverted U-type" correlation between WHtR and BMD (57). In addition, the existing research indicates that a greater WHtR is linked to a higher occurrence of hip fracture and spine fracture (58, 59). The current research used multivariable regression analysis to account for any confounding factors and ensure the generalizability of the findings to the elderly population in the United States. This approach differs from earlier studies. Our dose-response study revealed that there is a non-linear connection between WHtR and OP, specifically an *L*-type relationship with an inflection point value of 0.57. Within the specified range, the WHtR has a negative correlation with OP. However, once the ratio surpasses the specified threshold, this correlation ceases to exist. This outcome serves as a helpful addition to the existing body of research. Hence, we hypothesize that when the WHtR is less than 0.57, changes in variables such as mechanical stress and hormone may have a good influence on bone health. However, when the WHtR is equal to or greater than 0.57, the bad effects of belly fat buildup, changes in body composition, inflammation, insulin resistance, and other things may cancel out the good effects on bones that have already been shown. Furthermore, the connection remained strong and consistent in sensitivity and subgroup analysis.

The global prevalence of obesity has increased significantly and rapidly in recent decades, reaching epidemic levels (60). Defined as a medical condition characterized by excessive fat accumulation, obesity reduces life expectancy and is associated with various illnesses such as type 2 diabetes mellitus, hypertension, cardiovascular disease, depression, cancer, and OP (61). While several recent studies have explored the link between obesity and OP, the relationship between obesity and bone metabolism remains complex and somewhat unclear. Here are some potential mechanisms to consider: Obesity may impact bone metabolism through various factors, including mechanical stress, hormones, adipokines, cytokines, and other elements. This influence can be broadly categorized into positive and negative effects. On the positive side, obesity can increase bone density to cope with heightened mechanical stress (62). Elevated fat content is associated with increased estrogen production, which promotes the growth of osteoblasts and inhibits bone breakdown (63, 64). On the other hand, obesity increases the risk of insulin resistance, which may lead to a reduction in the differentiation and multiplication of osteoblasts and an increase in the production of osteoclasts (65-69). Additionally, obesity may lead to systemic low-level inflammation, resulting in increased osteoclast activity and bone breakdown (61, 70). Besides, leptin and adiponectin are the main adipokines secreted by adipose tissue. Obesity may elevate leptin levels and reduce adiponectin levels, which has been demonstrated to enhance osteoclast activity and result in bone loss (71). Furthermore, obesity has been shown to stimulate the transformation of bone marrow

TABLE 2 Association of covariates and osteoporosis risk.

Variables	OR (95% CI)	<i>p</i> _value
Age	1.09 (1.07, 1.11)	<0.001
Gender		
Male	1 (reference)	
Female	4.67 (3.68, 5.94)	<0.001
Race	1	
Non-Hispanic White	1 (reference)	
Non-Hispanic Black	0.35 (0.24, 0.50)	<0.001
Mexican American	0.84 (0.61, 1.15)	0.265
Other Hispanic	1.03 (0.69, 1.53)	0.902
Other Race*	1.46 (1.05, 2.04)	0.024
PIR	0.79 (0.73, 0.85)	<0.001
Education level		
Less than high school	1 (reference)	
High school or equivalent	0.80 (0.61, 1.05)	0.100
Above high school	0.60 (0.47, 0.75)	<0.001
Smoking status		
Never	1 (reference)	
Former	0.59 (0.47, 0.74)	<0.001
Now	1.15 (0.83, 1.59)	0.383
Drinking status	1	
Never	1 (reference)	
Former	0.67 (0.51,0.87)	0.004
Mild	0.47 (0.36,0.61)	<0.001
Moderate	0.42 (0.26,0.68)	<0.001
Heavy	0.71 (0.44,1.14)	0.151
CVD		
No	1 (reference)	
Yes	1.19 (0.93,1.53)	0.173
Hypertension		
No	1 (reference)	
Yes	0.93 (0.73,1.18)	0.545
DM		
No	1 (reference)	
Yes	0.71 (0.55,0.93)	0.013
HbA1c (%)	0.80 (0.71,0.91)	0.001
ALT (u/L)	0.97 (0.95,0.98)	<0.001
AST (u/L)	1.0 (0.99,1.01)	0.562
Serum total bilirubin(mg/dl)	0.48 (0.31,0.75)	0.001
Serum creatinine (mg/dl)	0.90 (0.68,1.20)	0.464
Uric acid (mg/dl)	0.74 (0.68,0.82)	<0.001
BUN (mg/dl)	1.01 (0.99,1.02)	0.233
Serum sodium (mmol/L)	1.01 (0.98,1.05)	0.524
Serum phosphorus (mg/dl)	1.92 (1.58,2.33)	<0.001
total calcium (mg/dl)	0.84 (0.63,1.13)	0.257
Serum potassium (mmol/L)	1.24 (0.93,1.64)	0.135
Serum iron (ug/dl)	1.0 (0.99,1.00)	0.064

Q, quartiles; OR, odds ratio; CI, confidence interval; * Other not defined by The NHANES but it does include multi-racial and non-Hispanic Asian; PIR, poverty-to-income ratio; CVD, Cardiovascular Disease; DM, diabetes mellitus; HbA1c, hemoglobin A1c; ALT, alanine transaminase; AST, alanine transaminase; BUN, blood urea nitrogen.

TABLE 3 Association between WHtR and osteoporosis.

WHtR	No.	Crude OR (95%Cl)	<i>p</i> -value	Model 1 OR (95% CI)	<i>p</i> -value	Model 2 OR (95% CI)	<i>p-</i> value	Model 3 OR (95% CI)	<i>p</i> -value
Q1 [0.36, 0.56]	1,437	1 (Ref)		1 (Ref)		1 (Ref)		1 (Ref)	
Q2 [0.56,0.61]	1,436	0.55 (0.43, 0.72)	< 0.001	0.64 (0.48, 0.84)	0.002	0.61 (0.45, 0.82)	0.001	0.63 (0.47, 0.85)	0.003
Q3 [0.61,0.66]	1,436	0.46 (0.33, 0.63)	< 0.001	0.54 (0.39, 0.75)	< 0.001	0.54 (0.38, 0.76)	< 0.001	0.53 (0.37, 0.76)	<0.001
Q4 [0.66,0.94]	1,437	0.41 (0.30, 0.55)	< 0.001	0.42 (0.31, 0.58)	< 0.001	0.49 (0.35, 0.68)	<0.001	0.49 (0.35, 0.68)	< 0.001
Trend test			< 0.001		<0.001		< 0.001		<0.001


WHtR, waist to height ratio; Q, quartiles; OR, odds ratio; CI, confidence interval; Ref, reference.

Crude: no other covariates were adjusted.

Model 1 was adjusted for gender, uric acid.

Model 2 was adjusted for model1 + age, race, poverty income ratio (PIR), educational level, smoking status, drinking status, diabetes mellitus (DM), hemoglobin A1c (HbA1c), alanine transaminase (ALT), serum total bilirubin, serum phosphorus.

Model 3 was adjusted for model2 + cardiovascular disease (CVD), hypertension, aspartate transaminase (AST), serum creatinine, blood urea nitrogen (BUN), serum sodium, total calcium, serum potassim, serum iron.



calcium, serum potassium, serum iron.

stem cells into fat cells, leading to a decrease in bone-forming cells in the bone marrow (70, 72, 73). Additionally, studies have found that obese individuals have lower levels of vitamin D, a crucial osteotropic factor, potentially due to factors such as dilution in body fluids, storage in fatty tissue, reduced sunlight exposure, and decreased production in the body (74).

This research has several constraints. Primarily undertaken among an elderly American demographic, more investigation is required to TABLE 4 Threshold effect analysis of the relationship of WHtR with osteoporosis.

WHtR	Crude m	odel	Adjusted model ⁺		
	OR (95%CI) ª	<i>p</i> -value	OR (95%CI) ª	<i>p</i> -value	
<0.57	0.41 (0.26,0.65)	<0.001	0.50 (0.31,0.82)	0.007	
≥0.57	0.83 (0.63,1.10)	0.199	0.86 (0.63,1.16)	0.316	

WHtR, waist to height ratio.

^aWHtR was entered as a continuous variable per increase 0.1.

OR, odds ratio; CI, confidence interval.

+Adjusted for age, gender, race, poverty income ratio (PIR), educational level, smoking status, drinking status, cardiovascular disease (CVD), hypertension, diabetes mellitus (DM), hemoglobin A1c (HbA1c), alanine transaminase (ALT), aspartate transaminase (AST), serum total bilirubin, serum creatinine, uric acid, blood urea nitrogen (BUN), serum sodium, serum phosphorus, total calcium, serum potassium, serum iron.

	nweighted patients/ tal NO.	Adiusted OR (95%CI)			nweighted patients/ tal NO.	Adiusted OR (95%CI)		P for interaction
Gender				Gender				0.078
Male				Female				
Q1[0.36, 0.56]	62/767	Reference	•	Q1[0.36, 0.56]	195/670	Reference	-	
Q2(0.56, 0.61]	36/817	0.35(0.21, 0.59)		Q2(0.56, 0.61]	118/619	0.74(0.50, 1.10)	⊢_ ∎1	
Q3(0.61, 0.66]	30/795	0.30(0.17, 0.52)		Q3(0.61, 0.66]	95/641	0.62(0.40, 0.96)		
Q4(0.66, 0.94]	23/625	0.47(0.28, 0.79)		Q4(0.66, 0.94]	92/812	0.51(0.35, 0.75)		
Race				Race				0.604
Non-Hispanic				Hispanic				
Q1[0.36, 0.56]	228/1260	Reference		Q1[0.36, 0.56]	29/177	Reference		
Q2(0.56, 0.61]	124/1144	0.62(0.45, 0.85)		Q2(0.56, 0.61]	30/292	0.60(0.27, 1.35)	· · · · · · · · · · · · · · · · · · ·	
Q3(0.61, 0.66]	101/1088	0.54(0.38, 0.79)		Q3(0.61, 0.66]	24/348	0.32(0.14, 0.71)		
Q4(0.66, 0.94]	87/1084	0.51(0.36, 0.73)		Q4(0.66, 0.94]	28/353	0.28(0.12, 0.67)	-	
Education level, y				Education level,	у			0.735
≤12				>12	107/1072	B-6		
Q1[0.36, 0.56]	70/359	Reference		Q1[0.36, 0.56]	187/1078	Reference		
Q2(0.56, 0.61]	54/415	0.69(0.41, 1.16)	•	Q2(0.56, 0.61]	100/1021	0.61(0.42, 0.90)		
Q3(0.61, 0.66]	40/420	0.39(0.22, 0.70)		Q3(0.61, 0.66]	85/1016	0.58(0.38, 0.87)		
Q4(0.66, 0.94]	47/462	0.43(0.21, 0.87)		Q4(0.66, 0.94]	68/975	0.51(0.34, 0.76)	⊢ −-∎−−-1	
Smoking status				Smoking status				0.833
Never				Former or curre	nt			
Q1[0.36, 0.56]	142/679	Reference	•	Q1[0.36, 0.56]	115/758	Reference	•	
Q2(0.56, 0.61]	90/695	0.76(0.48, 1.21)		Q2(0.56, 0.61]	64/741	0.53(0.35, 0.79)		
Q3(0.61, 0.66]	74/664	0.58(0.34, 0.98)		Q3(0.61, 0.66]	51/772	0.51(0.31, 0.84)	• B •	
Q4(0.66, 0.94]	60/668	0.58(0.35, 0.94)		Q4(0.66, 0.94]	55/769	0.40(0.25, 0.64)	⊢− ■−−+	
Drinking status				Drinking status				0.689
Never				Former or curre	nt			
Q1[0.36, 0.56]	51/220	Reference	÷	Q1[0.36, 0.56]	206/1217	Reference		
Q2(0.56, 0.61]	41/232	0.70(0.34, 1.42)		Q2(0.56, 0.61]	113/1204	0.60(0.44, 0.83)		
Q3(0.61, 0.66]	43/236	0.64(0.33, 1.26)	· · · · · · · · · · · · · · · · · · ·	Q3(0.61, 0.66]	82/1200	0.51(0.34, 0.76)		
Q4(0.66, 0.94]	36/242	0.58(0.29, 1.17)		Q4(0.66, 0.94]	79/195	0.47(0.33, 0.67)		
DM								0.680
				DM				0.000
No Q1[0.36, 0.56]	225/1205	Reference	1	Yes				
				Q1[0.36, 0.56]	32/232	Reference		
Q2(0.56, 0.61]	119/1057	0.62(0.44, 0.89)		Q2(0.56, 0.61]	35/379	0.79(0.38, 1.64)		
Q3(0.61, 0.66]	79/933	0.49(0.32, 0.75)		Q3(0.61, 0.66]	46/503	0.80(0.38, 1.68)		
Q4(0.66, 0.94]	67/796	0.47(0.32, 0.69)		Q4(0.66, 0.94]	48/641	0.66(0.31, 1.41)		

FIGURE 3

Association between WHtR and OP according to the general characteristics. WHtR, waist to height ratio; OP, osteoporosis. Except for the stratification factor itself, the stratifications were adjusted for all variables (age, gender, race, poverty income ratio, educational level, smoking status, drinking status, cardiovascular disease (CVD), hypertension, diabetes mellitus, hemoglobin A1c, alanine transaminase (ALT), aspartate transaminase (AST), serum total bilirubin, serum creatinine, uric acid, blood urea nitrogen (BUN), serum sodium, serum phosphorus, total calcium, serum potassium, serum iron). Squares indicate odds ratios (ORs), with horizontal lines indicating 95% CIs.

WHtR	No.	Crude OR (95%Cl)	<i>p</i> -value	Model 1 OR (95% CI)	<i>p</i> -value	Model 2 OR (95% CI)	<i>p</i> -value	Model 3 OR (95% CI)	<i>p</i> -value
Q1 [0.36, 0.56]	1,152	1 (Ref)		1 (Ref)		1 (Ref)		1 (Ref)	
Q2 [0.56, 0.61]	1,152	0.68 (0.49, 0.94)	0.019	0.78 (0.56, 1.09)	0.141	0.76 (0.53, 1.09)	0.133	0.78 (0.54, 1.13)	0.184
Q3 [0.61, 0.66]	1,152	0.44 (0.31, 0.63)	< 0.001	0.51 (0.35, 0.74)	< 0.001	0.48 (0.33, 0.70)	< 0.001	0.47 (0.32, 0.70)	< 0.001
Q4 [0.66,0.94]	1,153	0.46 (0.33, 0.63)	< 0.001	0.47 (0.34, 0.66)	< 0.001	0.52 (0.37, 0.74)	< 0.001	0.52 (0.36, 0.76)	0.001
Trend test			<0.001		<0.001		<0.001		<0.001

TABLE 5 Association between WHtR and osteoporosis after adjusting for the covariate of vitamin D.

WHtR, waist to height ratio; Q, quartiles; OR, odds ratio; CI, confidence interval; Ref: reference.

Crude: no other covariates were adjusted.

Model 1 was adjusted for gender, uric acid.

Model 2 was adjusted for model1 + age, race, poverty income ratio (PIR), educational level, smoking status, drinking status, diabetes mellitus (DM), hemoglobin A1c (HbA1c), alanine transaminase (ALT), serum total bilirubin, serum phosphorus.

Model 3 was adjusted for model2 + cardiovascular disease (CVD), hypertension, aspartate transaminase (AST), serum creatinine, blood urea nitrogen (BUN), serum sodium, total calcium, serum potassim, serum iron, VitD.

ascertain the applicability of our results to other groups. Also, even when regression models, stratified analysis, and sensitivity analysis are used, it is not possible to completely rule out the effect of unknown or unmeasured variables, which may still cause residual confounding effects. Furthermore, we did not account for BMI as a covariate since there was a significant collinearity between WHtR and BMI. Additionally, due to limitations in sample selection, we were unable to directly compare the associations of BMI, WC, and WHR with osteoporosis within the same cohort. This restriction may have affected the generalizability and comparability of our findings. Consequently, our results may not fully represent the true relationships between these indices and osteoporosis. This limitation could have impacted our comprehensive assessment of osteoporosis risk factors. Given these constraints, future studies should consider conducting more in-depth analyses of the relationships between these obesity indices and osteoporosis within a single sample to provide a more comprehensive understanding. Ultimately, because of the inherent constraints of crosssectional research, it is not possible to establish a definitive cause-andeffect connection between WHtR and OP. Therefore, it is necessary to conduct further longitudinal studies to validate this link.

5 Conclusion

In conclusion, this study indicates that the association between WHtR and OP was not linear, exhibiting a point of inflection at around 0.57. Further prospective studies are required to investigate the correlation between WHtR and OP in the future. Additional research, particularly long-term studies, would be essential to confirm these results and investigate their mechanism of action.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found at: http://www.cdc.gov/nchs/nhanes.htm.

Ethics statement

The studies involving humans were approved by the NCHS Research Ethics Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

HL: Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft. JQ: Formal analysis, Methodology, Writing – review & editing. ZG: Conceptualization, Writing – original draft. CL: Supervision, Writing – review & editing. JC: Supervision, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors gratefully acknowledge the financial support from the Anhui Provincial Natural Science Foundation (2308085QB47), the Health Research Project of Anhui Province (AHWJ2022b091), the Fundamental Research Funds for the Central Universities (JZ2023HGQA0114), the University Natural Science Project of Anhui Province (KJ2021A0348), and the Fund of Anhui Medical University (2022xkj108).

Acknowledgments

The authors acknowledge Huanxian Liu (Chinese PLA General Hospital, Beijing) for his work on the NHANES database. His outstanding work, the NHANES R package, and the webpage made it easier for us to explore the NHANES database. The authors acknowledge Jie Liu of the Department of Vascular and Endovascular Surgery, Chinese PLA General Hospital for his contribution to the statistical support, study design consultations, and comments regarding the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. Sarafrazi N, Wambogo EA, Shepherd JA. Osteoporosis or low bone mass in older adults: United States, 2017-2018. *NCHS Data Brief.* (2021) 405:1–8. doi: 10.15620/cdc:103477

2. Zhang YW, Song PR, Wang SC, Liu H, Shi ZM, Su JC. Diets intervene osteoporosis via gut-bone axis. *Gut Microbes.* (2024) 16:2295432. doi: 10.1080/19490976.2023.2295432

 Mills ES, Hah RJ, Fresquez Z, Mertz K, Buser Z, Alluri RK, et al. Secondary fracture rate after vertebral osteoporotic compression fracture is decreased by anti-osteoporotic medication but not increased by cement augmentation. J Bone Joint Surg Am. (2022) 104:2178–85. doi: 10.2106/JBJS.22.00469

4. Tian H, Pan J, Qiao D, Dong X, Li R, Wang Y, et al. Adiposity reduces the risk of osteoporosis in Chinese rural population: the Henan rural cohort study. *BMC Public Health*. (2020) 20:285. doi: 10.1186/s12889-020-8379-4

5. Deng G, Yin L, Li K, Hu B, Cheng C, Wang L, et al. Relationships between anthropometric adiposity indexes and bone mineral density in a cross-sectional Chinese study. *Spine J.* (2021) 21:332–42. doi: 10.1016/j.spinee.2020.10.019

6. Li H, Xu QY, Ye YL, Chang B, Wang R, Li GW. Association between obesity and fracture risk in Chinese women above 50 years of age: a prospective cohort study. *BMC Public Health.* (2024) 24:28. doi: 10.1186/s12889-023-17494-7

7. Feng Q, Bešević J, Conroy M, Omiyale W, Woodward M, Lacey B, et al. Waist-toheight ratio and body fat percentage as risk factors for ischemic cardiovascular disease: a prospective cohort study from UK biobank. *Am J Clin Nutr.* (2024) 119:1386–96. doi: 10.1016/j.ajcnut.2024.03.018

8. Louie JCY, Wall-Medrano A. Editorial: waist-to-height ratio is a simple tool for assessing central obesity and consequent health risk. *Front Nutr.* (2023) 10:1277610. doi: 10.3389/fnut.2023.1277610

9. Chen LH, Liu YH, Chen SC, Su HM. Low obesity-related indices are associated with a low baseline calcaneus ultrasound *t*-score, and a rapid decline in *t*-score in a large taiwanese population follow-up study. *Nutrients*. (2023) 15:605. doi: 10.3390/nu15030605

10. National Center for Health Statistics. (2024). NHANES survey methods and analytic guidelines. Available at: (https://wwwn.cdc.gov/nchs/nhanes/AnalyticGuidelines.aspx).

11. Zipf G, Chiappa M, Porter KS, Ostchega Y, Lewis BG, Dostal J. National health and nutrition examination survey: plan and operations, 1999-2010. *Vital Health Stat.* (2013) 1:1–37. Available at: https://pubmed.ncbi.nlm.nih.gov/25078429/

12. Human Subjects Research. (2024). National Institutes of Health Office of extramural research. Available at: (http://grants.nih.gov/grants/policy/hs/hs_policies.htm).

13. Xue S, Zhang Y, Qiao W, Zhao Q, Guo D, Li B, et al. An updated reference for calculating bone mineral density *t*-scores. *J Clin Endocrinol Metab*. (2021) 106:e2613–21. doi: 10.1210/clinem/dgab180

14. Peng S, Zhang G, Wang D. Association of selenium intake with bone mineral density and osteoporosis: the national health and nutrition examination survey. *Front Endocrinol.* (2023) 14:1251838. doi: 10.3389/fendo.2023.1251838

15. Hendrickx G, Boudin E, Van Hul W. A look behind the scenes: the risk and pathogenesis of primary osteoporosis. *Nat Rev Rheumatol.* (2015) 11:462–74. doi: 10.1038/nrrheum.2015.48

16. Wu Q, Dai J. Racial/ethnic differences in bone mineral density for osteoporosis. *Curr Osteoporos Rep.* (2023) 21:670–84. doi: 10.1007/s11914-023-00838-y

17. Chen Z, Ye H, Li E, Lin Y, Jin C, Yang L. Lipid accumulation product, poverty income ratio, and bone mineral density in U.S. adults: a mediation analysis based on NHANES (2009-2020). *Front Nutr.* (2024) 11:1466288. doi: 10.3389/fnut.2024.1466288

18. Xiao PL, Fuerwa C, Hsu CJ, Peng R, Cui AY, Jiang N, et al. Socioeconomic status influences on bone mineral density in American men: findings from NHANES 2011-2020. Osteoporos Int. (2022) 33:2347–55. doi: 10.1007/s00198-022-06498-5

19. Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi A. A systematic literature review on obesity: understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. *Comput Biol Med.* (2021) 136:104754. doi: 10.1016/j.compbiomed.2021.104754

20. Wu B, Fu Z, Wang X, Zhou P, Yang Q, Jiang Y, et al. A narrative review of diabetic bone disease: characteristics, pathogenesis, and treatment. *Front Endocrinol.* (2022) 13:1052592. doi: 10.3389/fendo.2022.1052592

21. Laroche M, Pécourneau V, Blain H, Breuil V, Chapurlat R, Cortet B, et al. Osteoporosis and ischemic cardiovascular disease. *Joint Bone Spine*. (2017) 84:427–32. doi: 10.1016/j.jbspin.2016.09.022

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

22. Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bonemineral loss in elderly white women: a prospective study. *Lancet*. (1999) 354:971–5. doi: 10.1016/s0140-6736(99)01437-3

23. Do HJ, Shin JS, Lee J, Lee YJ, Kim MR, Nam D, et al. Association between liver enzymes and bone mineral density in Koreans: a cross-sectional study. *BMC Musculoskelet Disord.* (2018) 19:410. doi: 10.1186/s12891-018-2322-1

24. Liu C, Shao M, Lu L, Zhao C, Qiu L, Liu Z. Obesity, insulin resistance and their interaction on liver enzymes. *PLoS One*. (2021) 16:e0249299. doi: 10.1371/journal. pone.0249299

25. Wu J, Su J, Wang Y, Chen J, Shang Y, Li J. Association between total bilirubin and bone mineral density level in adolescents. *BMC Musculoskelet Disord*. (2022) 23:639. doi: 10.1186/s12891-022-05592-3

26. Jenko-Pražnikar Z, Petelin A, Jurdana M, Žiberna L. Serum bilirubin levels are lower in overweight asymptomatic middle-aged adults: an early indicator of metabolic syndrome? *Metabolism*. (2013) 62:976–85. doi: 10.1016/j.metabol.2013.01.011

27. Ji X, Hong J, Qu Z, Yang W, Wang Y, Lin J, et al. HemoglobinA1c is a risk factor for changes of bone mineral density: a mendelian randomization study. *Front Endocrinol.* (2022) 13:942878. doi: 10.3389/fendo.2022.942878

28. Yang J, Xia Y, Sun Y, Guo Y, Shi Z. Effect of lifestyle intervention on HbA1c levels in overweight and obese adults with type 2 diabetes across ethnicities: a systematic review and meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract.* (2023) 199:110662. doi: 10.1016/j.diabres.2023.110662

29. Ugur A, Guvener N, Işiklar I, Turan M, Erdal R, Haberal M. Osteoporosis after renal transplantation: single center experience. *Transplantation*. (2001) 71:645–9. doi: 10.1097/00007890-200103150-00011

30. Kjaergaard AD, Teumer A, Witte DR, Stanzick KJ, Winkler TW, Burgess S, et al. Obesity and kidney function: a two-sample mendelian randomization study. *Clin Chem.* (2022) 68:461–72. doi: 10.1093/clinchem/hvab249

31. Guan Y, Lu YH, Lei SF. Physical activities mediate the correlations between serum creatinine and bone mineral density in Chinese. *Clin Chim Acta*. (2022) 524:25–33. doi: 10.1016/j.cca.2021.11.025

32. Meherubin I, Nessa A, Huda MN, Yeasmin F, Afroz L, Mumu NS. Level of serum creatinine and creatinine clearance rate in obese female. *Mymensingh Med J.* (2021) 30:991–6. Availabe at: https://pubmed.ncbi.nlm.nih.gov/34605468/

33. Yan DD, Wang J, Hou XH, Bao YQ, Zhang ZL, Hu C, et al. Association of serum uric acid levels with osteoporosis and bone turnover markers in a Chinese population. *Acta Pharmacol Sin.* (2018) 39:626–32. doi: 10.1038/aps.2017.165

34. Zeng J, Lawrence WR, Yang J, Tian J, Li C, Lian W, et al. Association between serum uric acid and obesity in Chinese adults: a 9-year longitudinal data analysis. *BMJ Open.* (2021) 11:e041919. doi: 10.1136/bmjopen-2020-041919

35. Holm JP, Amar AOS, Hyldstrup L, Jensen JEB. Hyponatremia, a risk factor for osteoporosis and fractures in women. *Osteoporos Int.* (2016) 27:989–1001. doi: 10.1007/s00198-015-3370-0

36. Qu Z, Yang F, Yan Y, Hong J, Wang W, Li S, et al. Relationship between serum nutritional factors and bone mineral density: a mendelian randomization study. *J Clin Endocrinol Metab.* (2021) 106:e2434–43. doi: 10.1210/clinem/dgab085

37. Düğer H, Bostan H, Gül Ü, Uçan B, Hepşen S, Sakız D, et al. The importance of hypophosphatemia in the clinical management of primary hyperparathyroidism. *J Endocrinol Investig.* (2023) 46:1935–40. doi: 10.1007/s40618-023-02064-w

38. Song S, Cai X, Hu J, Zhu Q, Shen D, Heizhati M, et al. Correlation between plasma aldosterone concentration and bone mineral density in middle-aged and elderly hypertensive patients: potential impact on osteoporosis and future fracture risk. *Front Endocrinol.* (2024) 15:1373862. doi: 10.3389/fendo.2024.1373862

39. Sato H, Takai C, Kazama JJ, Wakamatsu A, Hasegawa E, Kobayashi D, et al. Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis. *Sci Rep.* (2020) 10:9882. doi: 10.1038/s41598-020-66945-3

40. Bjørke-Monsen AL, Mikalsen SM, Ueland GÅ, Aaseth J, Whist JE. Low serum sodium concentrations in patients with obesity normalizes with weight loss. *Clin Nutr ESPEN*. (2021) 41:405–11. doi: 10.1016/j.clnesp.2020.10.011

41. Amin MN, Siddiqui SA, Uddin MG, Ibrahim M, Uddin SMN, Adnan MT, et al. Increased oxidative stress, altered trace elements, and macro-minerals are associated with female obesity. *Biol Trace Elem Res.* (2020) 197:384–93. doi: 10.1007/s12011-019-02002-z

42. Ozata M, Durmus O, Yilmaz MI, Bolu E, Erdogan M, Ozdemir IC. The reninangiotensin- aldosterone system (RAAS) and its relation with calcium homeostasis in male obesity. *Med Sci Monit*. (2002) 8:CR430–4. Available at: https://pubmed.ncbi.nlm. nih.gov/12070434/ 43. Wang D, Yang Y. The relationship between serum 25-hydroxyvitamin d levels and osteoporosis in postmenopausal women. *Clin Interv Aging*. (2023) 18:619–27. doi: 10.2147/CIA.S405317

44. Hajhashemy Z, Shahdadian F, Ziaei R, Saneei P. Serum vitamin D levels in relation to abdominal obesity: a systematic review and dose-response meta-analysis of epidemiologic studies. *Obes Rev.* (2021) 22:e13134. doi: 10.1111/obr.13134

45. Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruszon-Moran D, Dohrmann SM, et al. National health and nutrition examination survey: analytic guidelines, 1999-2010. *Vital Health Stat.* (2013) 2:1–24. Available at: https://pubmed.ncbi.nlm.nih.gov/25090154/

46. Harrell FE. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Cham: Springer International Publishing (2015).

47. Yang Q, Zheng J, Chen W, Chen X, Wenet D, Chen W, et al. Association between preadmission metformin use and outcomes in intensive care unit patients with sepsis and type 2 diabetes: a cohort study. *Front Med.* (2021) 8:640785. doi: 10.3389/fmed.2021.640785

48. Cheung YM, Joham A, Marks S, Teede H. The obesity paradox: an endocrine perspective. *Intern Med J.* (2017) 47:727–33. doi: 10.1111/imj.13257

49. Fassio A, Idolazzi L, Rossini M, Gatti D, Adami G, Giollo A, et al. The obesity paradox and osteoporosis. *Eat Weight Disord*. (2018) 23:293–302. doi: 10.1007/s40519-018-0505-2

50. Qiao T, Luo T, Pei H, Yimingniyazi B, Aili D, Aimudula A, et al. Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study. *Cardiovasc Diabetol.* (2022) 21:225. doi: 10.1186/s12933-022-01670-x

51. Kim H, Lee SH, Kim BJ, Koh JM. Association between obesity and femoral neck strength according to age, sex, and fat distribution. *Osteoporos Int.* (2017) 28:2137–46. doi: 10.1007/s00198-017-4015-2

52. Gruneisen E, Kremer R, Duque G. Fat as a friend or foe of the bone. Curr Osteoporos Rep. (2024) 22:245–56. doi: 10.1007/s11914-024-00864-4

53. Huang ZP, Huang BX, Zhang H, Zhu MF, Zhu HL. Waist-to-height ratio is a better predictor of hyperuricemia than body mass index and waist circumference in Chinese. *Ann Nutr Metab.* (2019) 75:187–94. doi: 10.1159/000504282

54. Chen S, Guo XF, Yu SS, Zhou Y, Li Z, Sun YX. Anthropometric indices in adults: which is the best indicator to identify alanine aminotransferase levels? *Int J Environ Res Public Health.* (2016) 13:226. doi: 10.3390/ijerph13020226

55. National Institute for Health and Care Excellence. (2023). Obesity: Identification, assessment and management. . (https://www.nice.org.uk/guidance/cg189).

56. Siviero-Miachon AA, Spinola-Castro AM, de Martino Lee ML, Calixto AR, Geloneze B, Lazaretti-Castro M, et al. Visfatin is a positive predictor of bone mineral density in young survivors of acute lymphocytic leukemia. *J Bone Miner Metab*. (2017) 35:73–82. doi: 10.1007/s00774-015-0728-5

57. Lee J, Yoon I, Cha H, Kim HJ, Ryu OH. Inverted U-shaped relationship between obesity parameters and bone mineral density in Korean adolescents. *J Clin Med.* (2023) 12:5869. doi: 10.3390/jcm12185869

58. Kim H, Lee CW, Nam MJ, Choi YJ, Han K, Jung JH, et al. Association between body composite indices and vertebral fractures in pre and postmenopausal women in Korea. *PLoS One*. (2021) 16:e0254755. doi: 10.1371/journal.pone.0254755

59. Zheng R, Byberg L, Larsson SC, Höijer J, Baron JA, Michaëlsson K. Prior loss of body mass index, low body mass index, and central obesity independently contribute to higher rates of fractures in elderly women and men. *J Bone Miner Res.* (2021) 36:1288–99. doi: 10.1002/jbmr.4298

60. Blüher M. Obesity: global epidemiology and pathogenesis. *Nat Rev Endocrinol.* (2019) 15:288–98. doi: 10.1038/s41574-019-0176-8

61. Zhao P, Xu A, Leung WK. Obesity, bone loss, and periodontitis: the interlink. *Biomol Ther.* (2022) 12:865. doi: 10.3390/biom12070865

62. Hou J, He C, He W, Yang M, Luo X, Li C. Obesity and bone health: a complex link. *Front Cell Dev Biol.* (2020) 8:600181. doi: 10.3389/fcell.2020.600181

63. Leeners B, Geary N, Tobler PN, Asarian L. Ovarian hormones and obesity. *Hum Reprod Update*. (2017) 23:300–21. doi: 10.1093/humupd/dmw045

64. Fischer V, Haffner-Luntzer M. Interaction between bone and immune cells: implications for postmenopausal osteoporosis. *Semin Cell Dev Biol.* (2022) 123:14–21. doi: 10.1016/j.semcdb.2021.05.014

65. Su T, He Y, Huang Y, Ye M, Guo Q, Xiao Y, et al. Myeloid-derived grancalcin instigates obesity-induced insulin resistance and metabolic inflammation in male mice. *Nat Commun.* (2024) 15:97. doi: 10.1038/s41467-023-43787-x

66. Guntur AR, Rosen CJ. IGF-1 regulation of key signaling pathways in bone. *Bonekey Rep.* (2013) 2:437. doi: 10.1038/bonekey.2013.171

67. Tahimic CGT, Wang Y, Bikle DD. Anabolic effects of IGF-1 signaling on the skeleton. *Front Endocrinol.* (2013) 4:6. doi: 10.3389/fendo.2013.00006

68. Fulzele K, Clemens TL. Novel functions for insulin in bone. *Bone*. (2012) 50:452–6. doi: 10.1016/j.bone.2011.06.018

69. Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res. (2011) 26:677–80. doi: 10.1002/jbmr.321

70. Wang X, Yang S, He G, Xie L. The association between weight-adjusted-waist index and total bone mineral density in adolescents: NHANES 2011-2018. *Front Endocrinol.* (2023) 14:1191501. doi: 10.3389/fendo.2023.1191501

71. Guo M, Lei Y, Liu X, Li X, Xu Y, Zheng D. The relationship between weightadjusted-waist index and total bone mineral density in adults aged 20-59. *Front Endocrinol.* (2023) 14:1281396. doi: 10.3389/fendo.2023.1281396

72. Zong Q, Bundkirchen K, Neunaber C, Noack S. Are the properties of bone marrow-derived mesenchymal stem cells influenced by overweight and obesity? *Int J Mol Sci.* (2023) 24:4831. doi: 10.3390/ijms24054831

73. Vanhie JJ, Kim W, Ek Orloff L, Ngu M, Collao N, De Lisio M. The role of exerciseand high fat diet-induced bone marrow extracellular vesicles in stress hematopoiesis. *Front Physiol.* (2022) 13:1054463. doi: 10.3389/fphys.2022.1054463

74. Karampela I, Sakelliou A, Vallianou N, Christodoulatos GS, Magkos F, Dalamaga M. Vitamin D and obesity: current evidence and controversies. *Curr Obes Rep.* (2021) 10:162–80. doi: 10.1007/s13679-021-00433-1